circle

INVESTORS & MEDIA

INVESTOR OVERVIEW

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

03/11/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
SOUTH SAN FRANCISCO, Calif. , AND WASHINGTON , May 18, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS. Cytokinetics is a sponsor of the 2022 ALS Roundtables, the National
Toggle Summary Cytokinetics to Participate in the 2022 H.C. Wainwright Global Life Sciences Conference
SOUTH SAN FRANCISCO, Calif. , May 17, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to present virtually at the 2022 H.C. Wainwright Global Life Sciences Conference taking place May 23-26,
Toggle Summary Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil
FDA Plans to Convene Advisory Committee Meeting SOUTH SAN FRANCISCO, Calif. , May 17, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the Company recently participated in a mid-cycle communication meeting with the U.S.
Toggle Summary Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2022 Congress
SOUTH SAN FRANCISCO, Calif. , May 16, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late-Breaking Science presentations at Heart Failure 2022, an International Congress of the European Society of Cardiology taking place online and in Madrid, Spain from May